FWBI Insider Trading

Insider Ownership Percentage: 3.65%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $23,327.24

First Wave BioPharma Insider Trading History Chart

This chart shows the insider buying and selling history at First Wave BioPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

First Wave BioPharma Share Price & Price History

Current Price: $0.29
Price Change: Price Decrease of -0.01 (-3.33%)
As of 09/29/2023 01:00 AM ET

This chart shows the closing price history over time for FWBI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyze Any Stock Free

First Wave BioPharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2023Charles J CasamentoDirectorSell10$0.43$4.306,098View SEC Filing Icon  
8/31/2023Charles J CasamentoDirectorSell6,053$0.30$1,815.906,108View SEC Filing Icon  
7/3/2023James SapirsteinCEOSell3,349$1.54$5,157.4636,161View SEC Filing Icon  
7/3/2023Sarah RomanoCFOSell1,977$1.54$3,044.5817,476View SEC Filing Icon  
4/3/2023James SapirsteinCEOSell3,347$2.50$8,367.5039,510View SEC Filing Icon  
4/3/2023Sarah RomanoCFOSell1,975$2.50$4,937.5019,453View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for First Wave BioPharma (NASDAQ:FWBI)

2.45% of First Wave BioPharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FWBI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

First Wave BioPharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/16/2023State Street Corp11,797$32K0.0%-85.7%0.761%Search for SEC Filing on Google Icon
5/16/2023Armistice Capital LLC89,856$0.24M0.0%-69.4%5.797%Search for SEC Filing on Google Icon
5/11/2023Acadian Asset Management LLC13,258$35K0.0%-73.6%0.855%Search for SEC Filing on Google Icon
2/15/2023Armistice Capital LLC293,966$0.26M0.0%N/A35.418%Search for SEC Filing on Google Icon
11/15/2022State Street Corp82,593$0.12M0.0%+97.4%6.020%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.214,553$0.23M0.0%-26.8%1.285%Search for SEC Filing on Google Icon
5/12/2022Citigroup Inc.36,567$39K0.0%N/A0.219%Search for SEC Filing on Google Icon
2/14/2022GSA Capital Partners LLP81,543$0.12M0.0%N/A0.549%Search for SEC Filing on Google Icon
11/9/2021Parsons Capital Management Inc. RI16,819$47K0.0%N/A0.180%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.10,944$31K0.0%N/A0.117%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
First Wave BioPharma logo
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Read More on First Wave BioPharma

Today's Range

Now: $0.29
Low: $0.29
High: $0.32

50 Day Range

MA: $0.41
Low: $0.29
High: $0.61

52 Week Range

Now: $0.29
Low: $0.27
High: $16.38


510,725 shs

Average Volume

10,838,378 shs

Market Capitalization

$2.07 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of First Wave BioPharma?

First Wave BioPharma's top insider investors include:
  1. James Sapirstein (CEO)
  2. Sarah Romano (CFO)
  3. Charles J Casamento (Director)
Learn More about top insider investors at First Wave BioPharma.